Article Details

Confo Therapeutics raises $60 million to focus on agonistic GPCR antibodies - Labiotech

Retrieved on: 2024-07-26 11:00:15

Tags for this article:

Click the tags to see associated articles and topics

Confo Therapeutics raises $60 million to focus on agonistic GPCR antibodies - Labiotech. View article details on hiswai:

Summary

The article discusses how Confo Therapeutics, led by CEO Cedric Ververken, uses advanced biopharma technologies to develop GPCR-modulating therapies, focusing on agonistic GPCR antibodies for conditions like obesity and rare endocrine diseases, linking to tags like cell signaling, immunology, and receptor-specific therapies.

Article found on: www.labiotech.eu

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up